It’s megablockbuster halfsies for Sanofi, Amgen in next new cholesterol market

Tracy Staton

When is fighting a game of six of one, half dozen of the other? Could be when the contest is between and its PCSK9 inhibitor evolocumab, and and Regeneron's rival alirocumab. Despite some dramatic new data from the latter team–and a first-up filing with the FDA by –analysts figure on a dead heat once the drugs hit the .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS